Where Retatrutide Stands with the FDA
As of May 2026, retatrutide has not been submitted for FDA approval. Eli Lilly is conducting eight Phase 3 trials under the TRIUMPH program name — TRIUMPH-1 through TRIUMPH-8 — covering obesity, type 2 diabetes, obesity with osteoarthritis, and weight maintenance. The first two trials to report results, TRIUMPH-4 in December 2025 and TRIUMPH-1 in May 2026, were successful and demonstrated 28.7% and 28.3% average weight loss respectively. Remaining trials are expected to report results through 2026 and early 2027.
Expected NDA Submission Date
Based on the current trial timeline, the NDA submission to the FDA is expected in late 2026 or early 2027. Eli Lilly typically submits New Drug Applications after at least two positive Phase 3 trials, which they now have. However, the company may wait for additional trial results — particularly the diabetes trials (TRIUMPH-2 and TRIUMPH-3) and the cardiovascular outcomes data — to submit a comprehensive package that supports approval for multiple indications simultaneously.
Standard FDA Review Timeline
The standard FDA review period for a New Drug Application with priority review designation is 8 months. Without priority review, the standard review period is 12 months. Given the weight loss efficacy data — the highest ever recorded — retatrutide is likely to receive priority review. This means that if an NDA is submitted in late 2026, FDA approval could come as early as mid-to-late 2027. If the submission comes in early 2027, approval would likely follow by early 2028.
Approval Timeline in Other Markets
The European Medicines Agency, the UK’s MHRA, and other regulatory bodies typically review the same clinical data package as the FDA but follow their own timelines. EMA approval usually follows FDA approval by 3 to 6 months for obesity drugs. The UK’s MHRA, which now operates independently post-Brexit, has shown willingness to approve certain drugs ahead of the EMA. Australian TGA approval typically follows by 6 to 12 months. No regulatory submissions have been announced for any market as of May 2026.
What the Jake Terry Story Tells Us
Jake Terry, the 48-year-old from Austin profiled in Wired, buys retatrutide from grey market vendors because his daughter’s semaglutide prescription cost $500 per month. His story illustrates the demand that has built up while the regulatory process runs its course. The grey market exists because the drug works and people want it, regardless of approval status. That is the reality of the market, and it is unlikely to change until retatrutide becomes available through legitimate channels.
Leave a Reply